CCO Treatment Updates

Depression Associated With HCV Infection and Its Therapy: Impact on Patient Management

Risk and Mechanisms of Depression in HCV

Module 1 of 3

CME Program Director:
Rafael Esteban-Mur, MD

Faculty:
Michael R. Kraus, MD, PhD

CME CREDIT INFORMATION

Release Date: 03/28/07

Expiration Date: 03/27/08

Physicians: maximum of 0.75 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Michael R. Kraus, MD, PhD, discusses the risks of depression in patients infected with the hepatitis C virus and the mechanisms underlying this depression.

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarise the epidemiology of depression in HCV-infected patients
Describe potential mechanisms for HCV-related depression
Discuss data describing HCV-related morphologic and functional alterations in the central nervous system

Depression and Suicidal Risk Associated With HCV Treatment

Module 2 of 3

CME Program Director:
Rafael Esteban-Mur, MD

Faculty:
Charles L. Raison, MD

CME CREDIT INFORMATION

Release Date: 03/28/07

Expiration Date: 03/27/08

Physicians: maximum of 0.5 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Charles L. Raison, MD, discusses the adverse effect of depression associated with HCV therapy and the impact of depression on successful HCV treatment.

Learning Objectives

Upon completion of this activity, participants should be able to:

Cite the prevalence of depression during treatment with HCV therapy
Summarise the impact of depression on treatment outcomes in patients with hepatitis C
Recall the risk factors for development of depression during HCV therapy
Describe the risk of suicide in HCV-infected patients receiving therapy

Strategies for Preventing, Diagnosing, and Managing Depression in Patients Receiving HCV Therapy

Module 3 of 3

CME Program Director:
Rafael Esteban-Mur, MD

Faculty:
Martin Schaefer, MD

CME CREDIT INFORMATION

Release Date: 03/28/07

Expiration Date: 03/27/08

Physicians: maximum of 0.50 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Topics covered include:

Introduction
Diagnostic Tools for Depression
Time Course of Psychiatric Adverse Effects During HCV Therapy
Management of Depression Associated With HCV Therapy
Overview of Management Strategies for Patients Initiating HCV Therapy

Learning Objectives

Upon completion of this activity, participants should be able to:

List the diagnostic tools for evaluating depression
Describe the time course of psychiatric adverse effects during HCV therapy
Recall strategies for managing depression associated with HCV therapy

CCO Slidesets

Risk and Mechanisms of Depression in HCV

Format: Microsoft PowerPoint (.ppt) | File size: 489 KB

Depression and Suicidal Risk Associated With HCV Treatment

Format: Microsoft PowerPoint (.ppt) | File size: 556 KB

Strategies for Preventing, Diagnosing, and Managing Depression in Patients Receiving HCV Therapy

Format: Microsoft PowerPoint (.ppt) | File size: 510 KB

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.